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Abstract
Heterogeneity in breast carcinomas can be appreciated at 
various levels, from morphology to molecular alterations, 
and there are well-known genotypic-phenotypic correla-
tions. Clinical decision-making is strictly focused on the eval-
uation of tumor cells and is based on the assessment of hor-
mone receptors and of the HER2 status, by means of a com-
bination of immunohistochemical and in situ hybridization 
techniques. The tumor microenvironment (TME) also shows 
a multifaceted nature stemming from the different actors 
populating the intratumoral and the peritumoral stroma of 
breast carcinomas. Of note, we have now evidence that tu-
mor-infiltrating lymphocytes (TILs) are clinically meaningful 
as their quantification in the intratumoral stroma strongly 
correlates with good prognosis, in particular in triple-nega-
tive and HER2-positive breast cancer patients. Nevertheless, 
TILs are just one of the many actors orchestrating the com-
plexity of the TME, which is populated by immune and non-
immune cells (cancer-associated fibroblasts, cancer-associ-
ated adipocytes), as well as non-cellular components such as 
chemical inflammation mediators. In this review article we 
will overview the main features of the distinct cell compart-
ments by discussing (i) the potential impact the TME may 
have on the prognostic stratification of breast cancers and 
(ii) the possible predictive value of some markers in the con-
text of immunotherapy in light of the recent results of phase 
III studies in advanced and early triple-negative breast can-
cer patients. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Breast cancer is a heterogeneous disease composed of 
different subtypes with distinctive histological and mo-
lecular features. From a morphological standpoint, the 
diversity of breast cancer growth patterns is captured 
mainly by histological grade; nevertheless, the breast can-
cer stroma is also highly heterogeneous, and this may in-
fluence the clinical and radiological diagnosis of breast 
cancer. The 2019 WHO blue book describes the stromal 
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structure of carcinomas of no special type (NST) as ex-
tremely variable [1]. Invasive carcinomas of NST are typ-
ically associated with a dense and hard stroma rich in can-
cer-associated fibroblasts (so-called CAFs) that frequent-
ly show myofibroblastic differentiation. In other cases, 
the stroma is fibrotic with scant cellularity. Angiogenesis 
is generally marked around the tumor mass and readily 
outlined by specific endothelial markers. In contrast, in-
vasive lobular carcinomas (ILC) generally present with 
little host reaction or disturbance of the background ar-
chitecture, which renders its radiological and macroscop-
ical identification quite difficult. This corresponds to an 
almost normal stroma. Luminal ILC is reported to have a 
more proliferative CAF population (α-smooth muscle ac-
tin positive) compared to luminal NST carcinomas; an-
giogenesis is also more prominent, although vessels are 
generally less mature [2]. Finally, there are some special 
histological types showing unique stromal features, such 
as mucinous carcinomas and micropapillary carcinomas. 
Mucinous carcinomas feature cell clusters floating in 
lakes of mucin partitioned by delicate fibrous septa con-
taining capillary blood vessels [1]. Micropapillary carci-
nomas display a spongy stroma, characterized by clear 
and empty spaces around the cell clusters and a delicate 
stromal framework composed of fibroblasts and connec-
tive tissue [1].
At present, clinical decision-making is based on the 
evaluation of tumor cells and on the assessment of hor-
mone receptors (estrogen [ER] and progesterone [PR] re-
ceptors) and of the epidermal growth factor receptor 2 
(HER2) status, by a combination of immunohistochemi-
cal and in situ hybridization techniques. Of note, these 
analyses are strictly focused on the evaluation of tumor 
cells. Nevertheless, we are coming to terms that some cel-
lular elements populating the stroma, typically immune 
cells, may impact on prognosis and even prediction of 
response to specific therapies. For instance, tumor-infil-
trating lymphocytes (TILs) have reached level I evidence 
as a good prognostic factor in triple-negative (TNBC) and 
HER2-positive breast carcinomas and are now being in-
corporated in diagnostic practice [3, 4]. TILs are just one 
of the many actors orchestrating the complexity of the 
tumor microenvironment (TME), which is populated by 
a heterogeneous group of immune and non-immune 
cells, but also non-cellular components such as chemical 
inflammation mediators, which are often involved in sev-
eral metabolic pathways [5], immune-evasion strategies 
[6] and immunotherapy response [7].
In this review article we will overview the main features 
of the distinct cell compartments by discussing (i) the po-
tential impact the TME may have on the prognostic strat-
ification of breast cancers and (ii) the possible predictive 
value of some markers in the context of immunotherapy.
Tumor-Infiltrating Lymphocytes
Tumor-infiltrating lymphocytes (TILs) are defined as 
mononuclear immune cells that infiltrate tumor tissue [8] 
and constitute a continuous variable quantified as a per-
centage of area occupied by TILs/total stromal area on 
hematoxylin- and eosin-stained tumor sections [8] 
(Fig. 1). Recommendations by a panel of experts of the 
International Immuno-Oncology Biomarker Working 
Group on Breast Cancer [9] have been provided and con-
stitute the reference to follow to correctly report TILs [1, 
8]. A training website has also been developed (www.
tilsinbreastcancer.org).
A cut-off comprised between 50 and 60% of stromal 
area infiltrated by TILs has been largely used to define 
lymphocyte-predominant breast cancers (LPBCs) 
(Fig. 1), which account for about 11% of all invasive breast 
carcinomas [10]. TILs are more frequently observed in 
high-grade lesions, in TNBC and HER2-positive breast 
carcinomas [11–13]. In a recently reported cohort of 
breast carcinoma patients treated with neoadjuvant che-
motherapy, TIL mean values for TNBCs, HER2-positive 
carcinomas and luminal carcinomas were reported as 
28.5, 26.5 and 24%, respectively [14].
There are solid data supporting the association be-
tween high degree of TIL infiltration and good outcome 
in triple-negative and HER2-positive disease [10, 12, 15–
17]. High levels of TILs correlate also with high patho-
logical complete response (pCR) rates in the neoadjuvant 
setting in triple-negative [18, 19] and HER2-positive dis-
ease [19, 20]. Taken together, the evidence provided so far 
supports the assessment of TILs as a robust prognostic 
factor in TNBC and HER2-positive breast carcinomas 
treated with chemotherapy with level I evidence provided 
by the multiple retrospective analyses of prospective clin-
ical trial samples [4]. Therefore, it is not surprising that 
the latest 2019 WHO classification of breast tumors has 
acknowledged the importance of stromal response pat-
terns and in particular the relevance TILs are gaining as a 
prognostic marker [1]. In addition, an invasive carcino-
ma of NST with medullary pattern (or basal-like features) 
rather than the historical medullary carcinoma has been 
proposed [1]. In other words, medullary carcinomas are 
now best considered as part of a spectrum of TIL-rich 
breast cancers.
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Of note, a recent analysis of the prognostic value of 
TILs in surgically resected TNBC patients not treated 
with chemotherapy in the adjuvant setting has shown 
that a cut-off of 30% of TILs was able to identify patients 
with extremely good outcome, in the entire population 
and in stage I disease patients [21]. In addition, another 
analysis on the value of TIL evaluation in the context of 
HER2-positive disease has been reported for the Short-
HER study: patients with low TILs appeared to benefit 
from 1-year trastuzumab, whereas patients affected by 
tumors with high TILs did extremely well with both 1 
year and 6 months of trastuzumab-containing chemo-
therapy [22].
Taken together, these recent data may suggest possible 
strategies of chemotherapy de-escalation in specific sub-
sets of patients.
Although the wealth of data on TILs in breast carcino-
mas seems quite robust, controversies and open ques-
tions remain to be answered.
First, we have not completely teased out the reasons 
behind a more immunogenic nature of TNBC and HER2-





Fig. 1. An overview of the heterogeneity of stromal features across 
different breast carcinomas, including special histological types. 
a An example of immune-enriched cancer (so-called lymphocyte-
predominant breast cancer) with > 90% of stroma occupied by tu-
mor-infiltrating lymphocytes (TILs): the tumor cells aggregate in 
a solid growth pattern and show high nuclear grade. b A well-dif-
ferentiated tubular carcinoma showing dense fibroblastic stroma 
and rare TILs interspersed in the intratumoral stroma (< 5%). c An 
NST (no special type) carcinoma displaying a dense fibrosclerotic 
immune-desert stroma. d An example of intratumor heterogeneity 
in breast cancer with a mixed carcinoma showing opposite stromal 
features in the two components: fibrosclerotic stroma in the NST 
component colliding with the typical spongy stroma of the micro-
papillary component (inset). e, f The unique stroma of mucinous 
carcinomas is composed by a lake of mucin, which is typically im-





over, in the most frequent special histological type of 
breast cancer, invasive lobular carcinoma, TILs have 
shown an inverted pattern in terms of correlation with 
outcome, as they appear to be significantly associated 
with a dismal prognosis [12].
Second, a controversy remains concerning the associa-
tion between high levels of TILs and increased trastuzum-
ab benefit in HER2-positive disease. Data from the Fin-
HER trial showed for each 10% increase in TILs a signifi-
cant decrease in distant recurrence rates in patients 
randomized to the trastuzumab arm [16]. On the other 
hand, analysis of TILs in the N9831 adjuvant trial in pa-
tients with early-stage HER2-positive breast cancer 
showed that the presence of TILs was prognostically as-
sociated with recurrence-free survival in patients treated 
with chemotherapy, but not in patients treated with 
trastuzumab-containing chemotherapy [23].
Third, we should mention that in diagnostic practice 
we assess TILs on a mere count on morphological grounds, 
which is cost-effective and has an acceptable yet not bril-
liant reproducibility [24–26]. Moreover, TILs represent a 
heterogeneous aggregate of immune cells with different 
phenotypes, and each subtype plays a different role in in-
flammatory responses (Fig. 2).
T-lymphocytes (CD3+) are the main component of 
TILs [27, 28]. T-lymphocytes include CD4+, CD8+ and 
T-regulatory cells (Treg). CD4+ and CD8+ T-cells repre-
sent the most significant anti-tumor cells [29, 30]: CD8+ 
T-lymphocytes recognize specific tumor antigens such as 
MHC-I and exert anti-tumor activity in TME through the 
pro-inflammatory interferon-γ (IFN-γ) and granzyme-
perforin complex releases [31]; CD4+ T-lymphocytes are 
able to differentiate into specific effectors, including T-
helper-1 (Th1)(secreting IL-2, IFN-γ and IFN-α which 
increase the anti-tumoral activity of macrophages and 
natural killer, NK, cells) [32] and T-helper-2 (Th2) (se-
creting IL-4, IL-5, IL-6, IL-10 and IL-13 which increase 
the pro-tumoral activity of macrophages) [32]. Effective-
ly, TILs CD8+ and Th1 cytokines correlate with a favor-
able prognosis in many cancer types [33–35], whereas 
high levels of Treg cells in breast carcinomas are associ-
ated with an unfavorable prognosis [36–38]. Treg cells 
suppress T-cell activation [36], IFN-γ production [39] 
and the anti-tumor immune response. In addition, the 
association between an increase in Treg-circulating cells 
and breast cancer metastasis has been described [40].
A minor component of TILs is represented by B-lym-
phocytes and plasma cells, adaptive immune-system cells 
[41] whose presence in the TME has been identified in 
many cancer types [42, 43], including breast cancer [44]. 
B-cells have been reported in some studies to be found in 
up to 25% of all breast carcinomas [45–48], and they are 
often found in tertiary lymphoid structures with CD4+ 
and CD8+ T-cells and dendritic cells [49–51]. Similarly 
to T-cells, B-cells have been implicated in favorable sur-
vival rates in medullary breast cancer [52, 53] and com-
mon forms of breast cancer [54]. It has been reported that 
the inflammatory infiltrate associated with “medullary-
like carcinomas” contains also plasma cells of the IgA im-
munophenotype, in analogy to those described in normal 
breast tissue and in contrast to the few plasma cells of in-
filtrating ductal carcinoma that were found to be pre-
dominantly of the IgG type. It has been supposed that 
likely in all secretory organs, such as salivary glands, and 
the gastrointestinal tract, the microenvironment in mam-
mary glands is capable of attracting IgA precursors or IgA 
plasma cells. The predominance of IgA plasma cells in the 
majority of medullary carcinoma has been supposed to 
be a sign of a better functional preservation of this tu- 
mor [55].
Yeong et al. [56] used immunohistochemistry cou-
pled with NanoString measurement of mRNA expres-
sion of immunoglobulin metagenes to quantify tumor-
infiltrating B-cells and plasma cells in TNBC samples. 
The authors used CD38 antibodies to discriminate plas-
ma cells within tumors, as CD138 immunocytochemical 
staining was also present on tumor cells. Multivariate 
analysis revealed that TNBCs with high intratumoral 
CD38+ plasma cell density were associated with longer 
disease-free survival independently of clinicopathologi-
cal parameters, and of the densities of tumor-infiltrating 
T-cells and B-cells. Immunoglobulin gene IGKC, IGHM 
and IGHG1 mRNA expression correlated specifically 
with the density of CD38+ plasma cells. After adjusting 
the multivariate analysis for the effect of intratumoral 
CD38+ plasma cell density, the expression levels of all 
three genes lost the significant prognostic value, suggest-
ing a biologically important role of plasma cells. Of the 
three genes tested, IGHG1 conferred the highest added 
prognostic value for both disease-free survival and over-
all survival (OS), when coupled with CD38+ plasma cell 
density [56].
Inflammation, TILs and Tumor Mutation Burden
The tumor mutation load or tumor mutation burden 
(TML or TMB) is defined as the number of non-synony-
mous mutations somatically occurring in a tumor, poten-
tially generating neoepitopes that are able to improve the 
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Fig. 2. The tumor microenvironment (TME) in breast carcinomas. 
The picture summarizes the different cellular immune and non-
cellular components of the TME in breast carcinomas. Tumor-
infiltrating lymphocytes (TILs) are mainly represented by T-cells 
(CD3+) and include CD4+, CD8+ and T-regulatory cells (Treg). 
A minor component of TILs is represented by plasma cells and B-
cells, usually found in tertiary lymphoid structures (TLS) with 
CD4+ and CD8+ T-cells and dendritic cells. Natural killer (NK) 
cells secrete cytokines such as TNF-α (tumor necrosis factor) and 
interferon-γ (IFN-γ). Tumor-associated macrophages (TAMs) are 
able to polarize into different phenotypes, M1 and M2. Tumor-
associated neutrophils (TANs) can polarize into two distinct sub-
types: N1 TANs and N2 TANs. TANs are able to release neutrophil 
elastase. In addition, neutrophil-derived oncostatin M, released by 
granulocyte-macrophage colony-stimulating factor (GM-CSF)-
stimulated TANs, can induce breast cancer cell detachment. Can-
cer-associated fibroblasts (CAFs) are classified into four subtypes 
(CAF-S1 to CAF-S4). CAF-S1 and CAF-S4 types are intratumoral 
CAFs, CAF-S3 are representative of the extratumoral stroma and 
CAF-S2 are equally distributed in both environments. Cancer-as-
sociated adipocytes (CAAs) are involved in tumor progression, 
metastasis and therapy resistance by secretion of adipokine such 
as leptin and adiponectin. Breast carcinomas need new blood ves-
sels to maintain growth, ensure cell proliferation and fuel meta-
static dissemination: vascular endothelial growth factor (VEGF) 
represents the most important pro-angiogenic factor, released by 
multiple TME components. The complement, a crucial part of the 
innate immune system, has emerged as a major regulator of cancer 
immunity. Complement anaphylatoxins in the TME can exert a 





stimulation of the immune system against the tumor 
cells, recognized as carriers of “non-self” antigens.
Among all cancers, breast carcinomas are character-
ized by an intermediate level of TMB [57], which is 
higher in TNBC and HER2-positive carcinomas com-
pared to luminal carcinomas [58]. The mutation rate is 
the key value defining TMB, calculated as the number 
of mutations per mega-base of a genome. This can be 
devised by whole exome sequencing (WES) data (cum-
bersome in routine diagnostic practice) or from more 
feasible targeted panels, with a longitudinal coverage 
higher than 1.3 Mb in size (reviewed in Fancello et al. 
[59]). There is not a unique cut-off limit used to discern 
between high-TMB and low-TMB tumors: as pointed 
out by Samstein et al. [60] the right TMB cut-off cannot 
be completely gene panel-, histology- and clinical ques-
tion-agnostic.
Syllogistic simplifications virtually relate the number 
of immunogenetic mutations with recruitment of intra-
tumoral lymphocytes, and a positive correlation between 
TMB and immune infiltration has been initially reported 
across different tumor entities, including breast cancer 
[61]. However, recent works decouple this association in 
most neoplasms [62, 63], and this holds true also for 
breast carcinomas [64–66]. In these studies, the degree of 
immune cell enrichment was not evaluated by TIL raw 
counts, rather this information was extrapolated from 
analyses of immunophenotypic gene expression profiles 
(GEPs), obtained by using either RNA-sequencing [64] 
or RNA-based NanoString targeted panels [62]. Sprang-
er et al. [63] exploited the TCGA dataset to correlate the 
immune infiltration landscape with the number of ge-
nomic mutations focusing on melanomas, but also re-
porting GEPs and mutation count for about 10,000 tu-
mors, comprising a total number of 1,067 breast carcino-
mas. They stratified cases into non-inflamed, inter - 
mediate or inflamed tumors, taking into account a T-cell 
gene signature of 13 genes. Interestingly, the three in-
flammation groups did not significantly differ in terms 
of TMB, suggesting that mutation densities are not di-
rectly correlated with T-cell enrichment [63]. Similarly, 
a weak association between a different expression signa-
ture of 18 genes associated with T-lymphocytes and TMB 
values has been reported by Cristescu et al. [62], with an 
in silico analysis on the same TCGA database. In addi-
tion, the authors applied this signature on a selected co-
hort of patients who were subjected to pembrolizumab 
treatment from different clinical trials, including also 
ER-positive/HER2-negative and TNBC patients. From 
the so-called Pan-Cancer cohort (without a discrimina-
tion in terms of tumor type) they introduced a new con-
cept, in which a joint stratification through the combina-
tion of a high TMB and a high T-cell phenotype identi-
fied a subset of “super-responder” patients with a higher 
progression-free survival (PFS) compared to that ob-
tained when the two single parameters were considered 
alone [62]. In this context, when samples from the TCGA 
cohort were stratified using the three classes (TMBlow/ 
T-Celllow, TMBhigh/T-Cellhigh, TMBhigh/T-Cellhigh) about 
50% of breast carcinomas with a HER2-positive or a tri-
ple-negative phenotype clustered in the subset with at 
least high TMB or high T-cell phenotype but only a mi-
nority showed a concomitant high TMB/high T-cell phe-
notype [62].
More specifically, in breast cancer, RNA sequencing-
based immune metagenes have been shown to signifi-
cantly correlate with lower clonal heterogeneity in all sub-
types and with a trend for lower overall mutation, neoan-
tigen and copy number alteration loads in TNBC and 
HER2-positive cancers [66]. Conversely, in ER-positive 
carcinomas mutation load, neoantigen load and copy 
number alteration load were weakly but positively associ-
ated with immune infiltration, which reached signifi-
cance for overall mutation load only [66].
In TNBCs Karn et al. [65] found RNA sequencing-
based immune metagenes to correlate well with histolog-
ical TILs quantification and to be inversely associated 
with clonal heterogeneity and somatic copy number al-
teration levels. In addition, lymphocyte-rich TNBCs har-
boring a good prognosis had significantly lower mutation 
and neoantigen counts than did lymphocyte-poor 
TNBCs with poor prognosis. Taken together, these data 
may lead to hypothesize that immune-rich TNBCs may 
be under an immune surveillance that continuously elim-
inates many immunogenic clones, resulting in lower 
clonal heterogeneity [65].
Still based on RNA-sequencing data, Thomas et al. 
[67] classified samples of TCGA and METABRIC breast 
cancer cohorts according to the level of infiltration (hot, 
warm and cold tumors) and observed an improved over-
all survival for patients with high TMB/hot tumors, re-
gardless of type of therapy. They confirmed higher levels 
of both TMB and immune cell infiltration in ER-negative 
patients; however, they observed an antithetical behavior 
for luminal and the triple-negative carcinomas: the worst 
survival curve for TNBC patients was characterized by a 
high mutation rate but a low infiltrate expression signal, 
whereas the best overall survival was observed in high 
TMB/hot luminal A carcinomas [67].
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Natural Killer Cells
Natural killer (NK) cells are cytotoxic lymphocytes 
participating in innate immunity that efficiently recog-
nize and kill tumor cells through several mechanisms in-
cluding the expression of ligands for NK cell-activating 
receptors on target cells (Fig. 2). Activated NK cells se-
crete a wide variety of cytokines such as TNF-α (tumor 
necrosis factor) and IFN-γ [68] and exert a cellular cyto-
lytic effect through the liberation of granzymes and cyto-
toxic perforins [69]. A recent meta-analysis has shown 
that breast cancer displayed variable expression of ligands 
for NK cell receptors, in particular NKG2D ligands and 
DNAM1 ligands [70]. A better survival for patients show-
ing higher expression of NCR3 (NKp30), NCR1 (NKp46), 
CD96, CRTAM, DNAM1 and NKG2D was also reported 
[71, 72].
Verma et al. [73] analyzed a series of breast cancer pa-
tients with locally advanced carcinomas subjected to neo-
adjuvant chemotherapy and observed an association be-
tween increased NK cells in the blood and better patho-
logical responses. No differences in terms of NK cell 
population were observed in tissue specimens before and 
after treatment. On the other side, in HER2-positive car-
cinomas treated with trastuzumab-containing chemo-
therapy Muntasell et al. [74] observed that baseline tu-
mor-infiltrating NK cells were significantly associated 
with pCR. In addition, molecular signatures associated 
with NK cells seem to represent a predictive marker of 
relapse-free survival in breast carcinomas [75], and up-
regulation of GZMB, PRF1, NCR1, KIRs and KLRCs were 
also associated with breast cancer patient outcome [76].
It should be acknowledged that when tumors develop 
mechanisms of immune evasion, some of these mecha-
nisms include also downregulation of NK cell ligands 
such as NKG2D and DNAM1 receptors, which can there-
fore lead to inhibition of NK cell functions [77–80].
Macrophages
Macrophages are large mononuclear cells that belong 
to the phagocyte system and are one of the immune cell 
types more abundantly present in breast cancer TME [81] 
where they play a key role in tumor progression, immu-
nosuppression and therapy resistance [82–85] (Fig.  2). 
Tumor-associated macrophages (TAMs) display great 
plasticity and polarize into different phenotypes: classi-
cally activated (M1) and alternatively activated (M2) 
macrophages. The first one is polarized by Th1 cells and 
triggers anti-tumor immune responses [86]. Conversely, 
M2 macrophages are stimulated by Th2 cytokines such as 
transforming growth factor β1 (TGF-β1), IL-4 and IL-13 
[87], which activate STAT6 target genes [88] (suppress-
ing immune system functions) and promote tumor cell 
proliferation. M2 TAMs are the most frequent type in 
breast cancers [89] since during carcinogenesis TME 
most likely drives M1 to the M2 phenotype [90]. It is well 
known that macrophages are recruited to the tumor by a 
range of chemokines (including vascular endothelial 
growth factor, VEGF, and C-C chemokine ligand 2) and 
foster breast cancer progression in different ways: regu-
lating stroma invasion and cell intravasation [91, 92], 
promoting angiogenesis [93] and metastasis [94, 95], and 
remodeling extracellular matrix (ECM) by metallopro-
teinase secretion [96]. Sousa et al. [97] reported a strong 
association between M2 levels and poor cancer differen-
tiation, ER-negative and basal-like subtypes. Moreover, 
many other studies have described a correlation between 
TAMs and higher histological grade, hormone receptor-
negative status, advanced stages and worse outcome [98, 
99]. Interestingly, bisphosphonate drugs, used in combi-
nation with hormonal therapy for breast cancer treat-
ment, are also known to exert an anti-macrophage activ-
ity [100]. In a study of postmenopausal women with lu-
minal carcinomas and receiving bisphosphonates disease 
recurrence and mortality were significantly reduced com-
pared to the patients who did not receive bisphosphonate 
therapy [101].
Neutrophils
Neutrophil granulocytes represent 50–70% of the leu-
kocytes present in human blood [102] and their ability to 
phagocytize and degrade external pathogens [103] is one 
of the characteristics that makes neutrophils the main 
cells of innate immunity. Neutrophils can efficiently mi-
grate to inflammatory sites due to the action of different 
factors. They are also present in numerous cancer models 
and in the TME (tumor-associated neutrophils, TANs) 
where they play an important role in pro- and anti-tu-
morigenic processes [104, 105] (Fig. 2). Similarly to mac-
rophages, neutrophils can polarize in two distinct sub-
types with opposite functions: N1 TANs show pro-in-
flammatory activity and induce CD8 T-cell activation, 
whereas N2 TANs inactivate T-lymphocytes [105] and 
promote cancer growth.
Albrengues et al. [106] described the mediator role of 





seminated dormant tumor cells in metastatic cells in a 
murine model. This process is the result of neutrophil 
elastase (NE) and matrix metalloproteinase-9 (MMP-9) 
action on laminin, which induce the proliferation of dor-
mant tumor cells by α3β1-integrin activation [106]. Ad-
ditionally, in an in vitro co-culture model the authors 
were able to demonstrate the ability of neutrophil-de-
rived oncostatin M, released by GM-CSF-stimulated neu-
trophils, to induce breast cancer cell detachment, pro-
mote the invasiveness capacity of MDA-MB-231 and 
T47D human breast cancer cells and induce breast cancer 
progression [107]. In this scenario, TANs may represent 
a source of oncostatin M for cancer cells, resulting in on-
costatin M-induced tumor progression and metastasis. In 
fact, the authors suggested that GM-CSF, released by 
breast cancer cells, stimulates neutrophils in producing 
oncostatin M and storing it in granules. Cell-to-cell con-
tact between neutrophil and breast cancer cells causes the 
release of oncostatin M from TANs, its binding to on-
costatin M receptors on breast cancer cells, increasing cell 
detachment, triggering tumor cell proliferation via acti-
vation of STAT3, VEGF secretion and invasiveness [107].
Recently, neutrophils have also been shown to be im-
portant for the survival and transport of circulating tu-
mor cells (CTCs) in blood vessels, by formation of CTC-
neutrophil clusters [108, 109], which probably protect 
CTCs facilitating their migration in other tissues [106, 
110, 111]. CTC-neutrophil clusters are characterized by a 
different genetic profile compared to CTCs alone, which 
makes them efficient metastatic precursors [108]. In fact, 
CTCs isolated from the CTC-neutrophil clusters present 
an increase in cellular replication capacity (also con-
firmed by higher levels of Ki-67) and a marked expression 
of the genes that code for TNF-α, OSM, IL-1β and IL-6 
[108].
Current evidence indicates that an increased neutro-
phil-to-lymphocyte ratio (NLR, obtained dividing the se-
rum neutrophil count by the lymphocyte count) assessed 
in blood samples, can have a predictive value for breast 
cancer patients not only in the early setting but also in the 
metastatic setting: the inflammatory status upon initial 
treatment, resumed by NLR values, is associated not only 
with a high recurrence rate, but also with the survival out-
come following recurrence [112]. Therefore, monitoring 
the NLR during the follow-up period may lead to early 
detection of patients who potentially have a higher risk of 
recurrence. In addition, Iwase et al. [112] demonstrated 
that TNBC had a significantly higher NLR at the time of 
recurrence and the highest change (an increase of 2.0) 
compared with the other subtypes.
Several studies and a recent meta-analysis have con-
firmed and extend the prognostic role of NLR in breast 
cancer [113–115]. However, Ferroni et al. [115] demon-
strated that the NLR may represent a negative prognostic 
factor to define distant metastasis-free survival, especially 
in stage I breast cancer, but not for local recurrence. Fol-
lowing their suggestions, the NLR prognostic value 
should be regarded with caution, and additional studies 
are required to consolidate the clinical value of NLR. Nev-
ertheless, in stage I patients the presence of a high NLR 
might raise the question as to whether they should be 
more aggressively managed [113–115]. Furthermore, a 
retrospective study was performed to investigate the role 
of NLR in breast cancer patients receiving neoadjuvant 
chemotherapy [116]: the pCR rate in patients with low 
pre-treatment NLR (NLR  < 2.06) was higher than in 
those with higher NLR (NLR  ≥ 2.06) (24.5 vs.14.3%, 
p  <  0.05). In addition, high NLRs were an independent 
significant predictor of lower relapse-free survival and 
breast cancer-specific survival in patients undergoing 
pre-operative chemotherapy.
Immunotherapy in Breast Cancer
Immunotherapy-based approaches in breast cancer 
have only recently gained strong evidence to enter clinical 
practice, and this is particularly true for TNBCs. In this 
context, the use of TILs and of other biomarkers of im-
munogenicity such as ligand 1 of programmed cell death 
protein 1 (PD-L1) expression seem to be playing a role in 
the prediction of response [117]. PD-L1 is the ligand 1 of 
the programmed cell death protein 1 (PD-1), which rep-
resents the predominant checkpoint present on both 
CD8+ and CD4+ T-cells. The results of the IMpassion130 
phase III study showed a clinical benefit from addition of 
atezolizumab (a monoclonal antibody targeting PD-L1) 
to nab-paclitaxel in patients with locally advanced/meta-
static TNBCs [118]. The median PFS was 7.5 months in 
the atezolizumab plus nab-paclitaxel arm versus 5 months 
in the placebo plus nab-paclitaxel arm (p < 0.0001) [118]. 
There was no significant difference in overall survival be-
tween the treatment groups in the intention-to-treat pop-
ulation; however, the data suggested a clinically meaning-
ful OS benefit with atezolizumab plus nab-paclitaxel in 
patients with PD-L1-positive status. A significant predic-
tor of response was indeed identified in PD-L1 expression 
in immune cells in more than 1% of the tumor area 
(Fig. 3). Thanks to these results in 2019 the US Food and 
Drug Administration has granted accelerated approval to 
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atezolizumab plus nab-paclitaxel as a first-line treatment 
for patients with unresectable locally advanced or meta-
static TNBCs showing PD-L1 expression on immune 
cells covering 1% or more of the tumor area (PD-L1 im-
mune-cell positive) [119]. More recently, the European 
Commission has also approved the combination of at-
ezolizumab plus nab-paclitaxel for the treatment of unre-
sectable locally advanced or metastatic TNBC patients 
with tumors that are PD-L1 positive (≥1% PD-L1 expres-
sion) who have not received previous chemotherapy for 
metastatic disease [120].
A key point is represented by the scoring system of 
PD-L1 expression and the assay that was used for the im-
munohistochemical test. Contrarily to other neoplastic 
diseases such as lung cancer, PD-L1 expression in breast 
cancer is mainly expressed in immune cells populating 
the stroma (prevalence of 41% of cases) rather than in tu-
mor cells (Fig. 3), where it can be rarely appreciated (less 
than 10% of cases) [118]. Since PD-L1 is mainly expressed 
in immune cells (ICs), it is not surprising that breast car-
cinomas with a certain degree of TILs are those likely to 
show PD-L1 expression. Nevertheless, PD-L1 can also be 
expressed by macrophages, neutrophils and dendritic 
cells. Indeed, in the IMpassion130 study PD-L1 expres-
sion was quantified in the whole immune cell compart-
ment, and the data show that the presence of PD-L1 in 
immune cells rather than mere TILs quantification or 
CD8+ phenotyping positively correlated with response: 
patients with TIL-positive tumors derived clinical benefit 
(in terms of PFS) only if their tumors were also PD-L1 
a b
c d
Fig. 3. Core biopsies of relapsed invasive breast carcinomas of no special type (NST) of triple-negative phenotype 
(a, b) assessed for PD-L1 expression by the SP142 assay (b, d): note in both cases the typical punctuate dark brown 





IC-positive; similarly, patients with CD8-positive tumors 
only derived clinical benefit if their tumors were also PD-
L1 IC-positive [121].
In IMpassion130, evaluation of both primary tumors 
and metastatic deposits was allowed, and no difference 
was observed in predicting response according to type of 
specimen evaluated [118]. Still we do not have data on 
direct comparison of paired primary tumor and meta-
static sites from the same patient. From a post-hoc analy-
sis performed on the study we know that immunogenic-
ity may vary according to the metastatic site, with liver 
metastases displaying the lowest level of IC infiltration 
overall [122].
A major debate relates to the interchangeability of anti-
PD-L1 antibodies in diagnostic practice, a topic of major 
interest for pathologists. In the IMpassion130 study, the 
SP142 assay was used, and the Food and Drug Adminis-
tration approved the drug with this specific companion 
diagnostic. Tumor specimens of the IMpassion130 cohort 
have been further analyzed by means of two other clones 
used in diagnostic practice, the SP263 and the 22C3 with 
corresponding scoring systems (Table 1). The 22C3 and 
the SP263 identify a larger number of positive cases (81 
and 75%, respectively) compared to SP142 (46%), and a 
significant correlation with response to atezolizumab was 
observed also for all of the clones [122]. However, it is im-
portant to consider that the subpopulation of cases posi-
tive for SP263 and/or the 22C3 but negative for SP142 
does not show PFS advantage in the atezolizumab arm, 
thus demonstrating that the clinical benefit observed for 
the other two clones is driven by the positive population 
that is identified by the SP142 clone [122]. In addition, the 
SP142 assay identified patients with the smallest hazard 
ratio point estimates and longest median PFS and OS from 
atezolizumab plus nab-paclitaxel [122].
In the context of immunotherapy approaches in breast 
cancer, it should also be acknowledged that results on ear-
ly TNBCs treated in neoadjuvant studies with combina-
tion of chemotherapy and immunotherapy are now avail-
able. The phase III KEYNOTE-522 trial has recently 
shown significantly higher pCR rates for those patients 
treated with the addition of pembrolizumab to chemo-
therapy [123]. Although a higher pCR rate was observed 
for the PD-L1-positive tumors, the difference was not sta-
tistically significant. Of note, the PD-L1 evaluation in this 
study was carried out by using the combined positive 
score, which takes into account tumor and stromal cell 
expression (Table 1).
Taken together, on one side the available data high-
light the efficacy of new therapeutic agents in a disease 
Table 1. Ligand 1 of programmed cell death protein 1 (PD-L1) quantification by immunohistochemistry in triple-negative breast carci-
nomas (TNBCs): summary of different scoring methods applied in different clinical studies
Combined positive score (CPS) Immune cell (IC) algorithm Immune cell (IC) algorithm
Antibody clone 22C3 (Dako Agilent) SP142, SP263 (Roche-Ventana) SP263 (Roche-Ventana)
Target cells Tumor cells and immune cells Immune cells only Immune cells only
Formula (Number of PD-L1 staining cells 
(tumor cells, lymphocytes, 
macrophages)/the total viable tumor 
cells) ×100
Any staining in immune cell/tumor 
area (tumor area = area occupied by 
tumor cells, associated intratumoral 
and continuous peritumoral stroma)
Any staining in immune cell/tumor 
area (tumor area = area occupied by 
tumor cells, associated intratumoral 
and continuous peritumoral 
stroma)
Cut-off >1% >1% >1%
Minimal requirement for testing At least 100 viable tumor cells At least 50 tumor cells with viable 
stroma
At least 50 tumor cells with viable 
stroma
Clinical study in which it was 
originally applied 
(immunotherapy combination 
used in the experimental arm)
KEYNOTE-522 (pembrolizumab 
plus a sequence of carboplatin + 
paclitaxel followed by doxo/
epirubicin + cyclophosphamide)
IMpassion130 (atezolizumab + nab-
paclitaxel)
Prevalence of PD-L1 positivity 
in the IMpassion130
81% 46% 75%
Analysis of specimens from 
other studies
Yes, post-hoc analysis of 
IMpassion130 samples
No Yes, post-hoc analysis of 
IMpassion130 samples
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with high unmet needs (TNBC patients). On the other 
side, the possible biomarkers predicting response to treat-
ment are yet to be fully elucidated, including the precise 
role of PD-L1 expression in relation to timing of expres-
sion (primary tumors vs. residual disease, relapses, meta-
static deposits) and disparities among technical assays 
that may impact on patient selection.
Cancer-Associated Fibroblasts
Cancer-associated fibroblasts (CAFs) are the main cell 
component of the breast cancer stromal compartment, 
which is usually desmoplastic with some exceptions in 
histological special types of breast cancer such as micro-
papillary carcinomas, mucinous carcinomas or medul-
lary-like carcinomas, thus highlighting a certain degree of 
heterogeneity also in the stromal compartment of breast 
cancer (Fig. 1).
CAFs are able to secrete a number of proteases, which 
enhance their ability to migrate and remodel ECM [124]; 
they have been shown also to secrete inflammatory mol-
ecules and growth factors, which are capable of recruiting 
inflammatory cells in neoplastic sites [125].
In a recent meta-analysis, a high density of fibroblasts 
was associated with worse clinical outcome, poor tumor 
differentiation and lymph node metastasis in breast car-
cinomas [126]. Moreover, collagen density can reduce the 
number of CD8+ TILs in breast tumors and modulate T-
cell cytotoxic activity [127]. By using in vivo heterotypic 
cell recombinant models, Dumont et al. [128] demon-
strated that CAFs can promote a mesenchymal pheno-
type acquisition both in pre-malignant and malignant 
mammary epithelial cells, and modulate dissemination, 
tumorigenesis and metastasis of breast cancer cells 
through deposition of a distinct ECM characterized by 
aligned collagen fibers/deposits. A recent study on mouse 
models of TNBC has shown that the hedgehog ligand 
produced by neoplastic cells mediates CAF reprogram-
ming leading to stemness and chemoresistance via FGF5 
expression and production of fibrillar collagen [129]. In-
terestingly, the use of smoothened inhibitors (SMOi) for 
stromal treatment on patient-derived xenografts seems to 
be able to mediate downregulation of cancer stem cell 
marker expression and to sensitize cells to taxanes that 
reduced metastatic disease and improved survival. These 
in vivo data, coupled with evidence from phase I studies 
of efficacy of the combination of SMOi and docetaxel, 
pose the preclinical bases for a potential new therapeutic 
target choice in TNBC patients [129].
Interestingly, Costa et al. [130] have recently identified 
distinct CAF subsets (S1–S4) in breast cancer stroma by 
means of multicolor flow cytometry and concomitant 
analysis of distinct fibroblast marker expression levels. 
CAF-S1 and CAF-S4 types are intratumoral CAFs and are 
more present in HER2-positive carcinomas and TNBCs, 
CAF-S3 cells are representative of the extratumoral stro-
ma, and CAF-S2, equally distributed in both environ-
ments, are enriched in luminal A carcinomas. Further-
more, CAF-S1 and CAF-S4 show distinct genetic profiles 
and different characteristics: CAF-S4 seems to be respon-
sible for muscle contraction, actin-cytoskeleton and oxi-
dative metabolism regulation, whereas the CAF-S1 type 
is involved in ECM organization and contributes to the 
formation and maintenance of an immunosuppressive 
microenvironment by attracting and increasing the sur-
vival of CD4+ CD25+ T-cells, promoting T-cell differen-
tiation into Treg and enhancing Treg-mediated inhibi-
tion of T effector proliferation [130]. Hence, breast carci-
noma tumors enriched in CAF-S1 may acquire resistance 
to immunotherapies, and it can be postulated that CAF-
S1 molecules provide potential targets that may pave the 
way for additional treatment strategies.
Cancer-Associated Adipocytes
Adipocytes represent a relatively abundant compo-
nent of breast parenchyma. Cancer-associated adipocytes 
(CAAs) differ from the normal adipocytes in size, meta-
bolic activity and adipokines expression [131, 132] and 
have been demonstrated to be involved in tumor progres-
sion, metastasis and therapy resistance by secretion of ad-
ipokines, such as leptin and adiponectin, and a series of 
inflammatory chemokines and interleukins [133, 134]. 
For instance, the increased leptin secretions observed in 
CAAs can promote cell proliferation and tumor angio-
genesis by upregulation of lysyl hydroxylase enzyme, ac-
tivation of ER, JAK/STAT3, PI3K/AKT and SRC-1 sig-
naling pathways, and by increasing cyclin D1 and VEGF/
VEGFR expression [132, 135]. Conversely, adiponectin 
(APN), which plays an anti-tumorigenic role by inducing 
apoptosis, suppressing growth and invasion of breast 
cancer cells through AMPK activation and PI3K/AKT in-
hibition, is decreased in CAAs [133]. An APN reduction 
was detected both in co-culture in vitro models and in 
CAAs located in human breast cancer tissues as com-
pared with normal mammary adipose tissue [136].
Cruz et al. [137] observed in in vitro models that leptin 





thus contributing to cell-cell adhesion weakening and in-
creasing the secretion of metalloproteases (MMP-2 and 
MMP-9) required for ECM remodeling and cell migra-
tion in TNBC cell lines. Another study has demonstrated 
that free fatty acids added to co-cultures of breast cancer 
cells and adipocytes were transferred to cancer cells, driv-
ing fatty acid metabolism, resulting in increased prolif-
eration and cell migration [138]. The upgraded serum 
levels of leptin have also been associated with higher 
pathological grade and aggressive phenotypes in breast 
cancer patients [139]. Produced by adipose tissues, IL-6 
is more secreted in CAAs compared with other adipo-
cytes [131], and it has also been shown to promote cancer 
progression when adipocytes are co-cultured with breast 
cancer cells [140]. Furthermore, it has also been demon-
strated that IL-6 production can regulate cancer cell sur-
vival, immune suppression and drug resistance by JAK 
phosphorylation and STAT3 activation [141]. Interest-
ingly, it has been observed that PD-L1 expression in ma-
ture adipocytes negatively modulates the efficacy of im-
munotherapeutic agents in in vitro breast cancer models, 
by suppressing the antitumor-functions of CD8+ and 
CD4+ T-cells [142].
Microvascular Density in TME
Breast carcinomas need new blood vessels to maintain 
growth, ensure cell proliferation and fuel metastatic dis-
semination. A high microvascular density has been large-
ly associated with adverse clinical-pathological features 
(large tumor size, high histological grade, lymph node 
metastasis and poor prognosis) [143–145]. A wealth of 
data supports a central role of multiple TME components 
in angiogenesis by releasing pro-angiogenic factors such 
as VEGF, acid and basic fibroblast growth factor, trans-
forming growth factor-β1, hypoxia-inducible factors 
(HIF-1 and HIF-2) and mast cell-derived metalloprotein-
ases [146, 147].
VEGF represents the most important pro-angiogenic 
factor, shown to be over-expressed in several breast can-
cer models, and it has been correlated with OS in both 
node-positive and node-negative breast cancer [148, 
149]; it has also been related with impaired response to 
tamoxifen or chemotherapy in advanced breast cancer 
patients [150]. VEGF receptor-2 (VEGFR-2) is the pre-
dominant form that controls angiogenesis, and the regu-
lation of its expression has been investigated in several in 
vitro models with the aim of developing new pharmaco-
logical strategies to target cancer cell proliferation and 
survival [151]. Estrogen (E2) regulates VEGFR-2 in an-
giogenesis through complex mechanisms, involving both 
genomic and non-genomic effects. Higgins et al. [152] 
have demonstrated an E2-dependent down-regulation of 
VEGFR-2 expression in MCF-7 breast cancer cells, but 
also an E2-dependent stimulation of VEGFR-2 mRNA 
and protein expression in ZR-75 breast cancer cells [153]. 
In the latter scenario, it could be hypothesized that by 
blocking secretion of E2 angiogenesis would be inhibited 
[154].
Linderholm et al. [155] reported higher intratumoral 
VEGF levels and both shorter recurrence-free survival 
and OS in TNBC patients compared to non-TNBC sub-
groups.
Other factors contribute to increase the breast angio-
genic microenvironment. For instance, recent studies 
showed that CCL2/CCR2 signaling in breast cancer cells 
regulates tumor growth and invasion by promoting an-
giogenesis through the recruitment and branching of en-
dothelial cells, recruiting and polarizing macrophages to 
M2 phenotype, and suppressing cytotoxic T-cell activity 
[156]. Kim et al. [157] analyzed both the expression levels 
of Notch1, a signaling pathway involved in cell prolifera-
tion and angiogenesis, and microRNAs-34a in 114 TNBC 
samples and reported better OS in patients presenting 
low EC Notch1 (Notch1 microvascular density to CD34 
microvascular density ratio) than those with a high ratio, 
and a significant correlation between high microRNAs-
34a levels, decreased vessel formation (low EC Notch1 
levels) and higher survival benefit in a lymph-node-pos-
itive group [157].
The hypoxia is another pro-angiogenesis signal. HIF-
1α, one of the major transcription factors that lead hy-
poxic cells to up-regulate proteins that promote survival 
and increase growth of hypoxic tumor cells, is expressed 
in BRCA1-2 carrier [158]. HIF-1α is higher in poorly dif-
ferentiated than in well-differentiated lesions, and its in-
creased expression is also associated with increased ex-
pression of ER and VEGF [159]. IL-8, a chemotactic fac-
tor for neutrophils, is also known to be a powerful 
promoter of angiogenesis and, in oxidative stress states 
(such as inflammation conditions), IL-8 can be produced 
by the activation of endothelial cells and showed a meta-
static potential role, by mediating formation, in neutro-
phil-endothelial cell co-culture, of neutrophil extracellu-
lar trap (NET), also known as NETosis [160, 161]. NETs 
can promote inflammatory progression in TME causing 
endothelial damage and activating platelets that promote 
cell proliferation and neovascularization [161]. NETs are 
also a prognostic indicator of venous thromboembolism: 
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breast cancer patients present an increased risk (3–4 
times) of venous thromboembolism, also associated with 
lower survival benefit [162], and high plasma levels of 
citrullinated histone H3, a biomarker of NET formation, 
are predictive of relapse in several cancers including 
breast types [161].
Conclusions
Heterogeneity in breast carcinomas can be appreciated 
at various levels, from morphology to molecular altera-
tions, and there are well-known genotypic-phenotypic 
correlations. The TME also shows a multifaceted nature 
stemming from the different actors populating the intra-
tumoral and the peritumoral stroma of breast carcino-
mas, and this has been acknowledged in the latest WHO 
classification of breast cancer. TNBCs and HER2-positive 
carcinomas are more immune-enriched (“hot tumors”) 
compared to largely immune desert (“cold tumors”) lu-
minal carcinomas. TILs represent a strong indicator of 
good prognosis in TNBCs, and preliminary data are 
emerging suggesting de-escalation of therapy based on 
this biomarker. Nevertheless, a high level of TILs does not 
necessarily correlate with response to immune therapies. 
The IMPassion130 phase III study in metastatic breast 
cancer patients has shown that PD-L1 expression ob-
served in immune cells (including lymphocytes, macro-
phages, neutrophils, dendritic cells) is predictive of re-
sponse to the combination therapy of atezolizumab plus 
nab-paclitaxel. At present, for patients with PD-L1 im-
mune cell-positive metastatic TNBC, atezolizumab plus 
nab-paclitaxel is an important therapeutic option in a dis-
ease with high unmet needs. It should be acknowledged, 
however, that PD-L1 quantification represents a mea-
surement of only one of the many potential mechanisms 
of immune evasion used by tumor cells. Moreover, the 
role of PD-L1 expression is yet to be fully elucidated, as 
the available data on early breast cancer from the phase 
III neoadjuvant KEYNOTE522 study show a higher num-
ber of pCR rates in the pembrolizumab arm, regardless of 
the presence of PD-L1 expression. In this context, meth-
ods of quantification and scoring systems may also im-
pact, and pathologists seem to have a central role in guid-
ing the precise biomarker evaluation. Finally, there is ev-
idence to support an important role played by other 
components of the microenvironment; nevertheless, 
these features are yet to be incorporated in diagnostic al-
gorithms.
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